Inviragen Receives Two Therapeutic Discovery Project Grants for Vaccine Development
Fort Collins, CO and Madison, WI - November 2, 2010
Inviragen, a biotechnology company developing vaccines to
protect against infectious diseases worldwide, announced today that it has received two grants
totaling $488,958 through the United States government's Qualifying Therapeutic Discovery Project Program. The grants were awarded to
Inviragen for the Company's ongoing programs to develop vaccines against dengue and chikungunya
viruses. Inviragen is currently testing its dengue vaccine, DENVax, in two Phase 1 human clinical trials,
while the Company's experimental chikungunya vaccine is undergoing preclinical testing.
"The Department of Health and Human Services recognized the potential public health
impact of Inviragen's dengue and chikungunya vaccines," stated Dr. Dan Stinchcomb, Inviragen's CEO.
"The funds will permit Inviragen to accelerate our clinical and preclinical vaccine studies."
The Qualifying Therapeutic Discovery Project Program was established by the
Patient Protection and Affordable Care Act in March 2010 to provide tax credits and grants to small
biotechnology firms (as defined by those with 250 employees or fewer) that show significant potential
to produce breakthrough medical therapies, create or sustain jobs, and increase U.S. competitiveness.
About Inviragen, Inc.
Inviragen is focused on developing vaccines to protect against infectious diseases
worldwide. Inviragen's lead product candidate is a vaccine to protect against dengue fever.
Inviragen is also developing vaccines to protect against hand, foot and mouth disease and
Japanese encephalitis, both of which affect millions of children in Asia. Vaccines in preclinical
research stages include a chikungunya vaccine, a low-cost human papilloma virus vaccine,
vaccines to protect against new forms of influenza, a vaccine to protect against West Nile and a
combination plague/smallpox vaccine for biodefense. Inviragen has offices in Colorado,
Wisconsin and Singapore. Please see
www.inviragen.com for more details.
Contact at Inviragen
Dr. Dan Stinchcomb
+1.970.372.4754
dstinchcomb@inviragen.com
Media Contact:
Aline Schimmel
+1.312.238.8957
aschimmel@scientapr.com
|
